Patent 12193790

Assignment history

Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.

Active provider: Google · gemini-2.5-flash

Ownership chain (1)

Asserters network →

Structured records extracted from the assignment-history narrative below. Each entity links to its full ownership-network profile.

  1. 2024-02-09 · recorded 2024-02-12 · reel 062638/0879 · Assignment

    ISLAM, MOHAMMED N.OMNI MEDSCI, INC.

    Correspondent: · OMNI MEDSCI, INC.

    internal reorg

Assignment history

Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.

✓ Generated

Inventors

The sole named inventor is Mohammed N. Islam. At the time of filing, Mr. Islam was the founder and Chief Technology Officer of Omni Medsci Inc. and also held professorships at the University of Michigan, with his research interests spanning defense and healthcare applications of mid- and near-infrared laser sources. The assignment of the patent from Mr. Islam to Omni Medsci Inc. on the same day the application was filed indicates a transfer within his own corporate structure, and does not suggest an unusual pattern of departure.

Original Assignee

The original assignee on the issued patent is Omni Medsci Inc.

  • Shipped a product embodying the claims: No. Omni Medsci Inc. does not assert that it manufactures or sells patented products. Instead, it states that it seeks to commercialize its patents by entering into partnerships with other companies.
  • Primary line of business: Patent commercialization and assertion, particularly focusing on optical technology for healthcare applications developed by its founder, Mohammed N. Islam. The company is actively involved in patent litigation against manufacturers of wearable devices.
  • Current status: Operating and actively engaged in patent assertion. The patent is currently involved in litigation, including PTAB cases and US District Court cases.

Assignment timeline

  • 2024-02-09 (executed) / recorded 2024-02-12 — Reel 062638/0879
    • Conveyance: ASSIGNMENT
    • Assignor: ISLAM, MOHAMMED N.
    • Assignee: OMNI MEDSCI INC.
    • Correspondent: OMNI MEDSCI, INC. 4800 PLYMOUTH ROAD ANN ARBOR, MI 48105
    • Context: Transfer of patent rights from the individual inventor to his company, Omni Medsci Inc.

Timeline diagram

timeline
    title Ownership of US 12193790
    2024 : Filed by Omni Medsci Inc
         : Assigned from inventor to Omni Medsci Inc
    2025 : Issued
         : Litigation initiated

NPE / troll-pattern signals

  1. Shell-entity transfer — Unclear. The only recorded transfer is the initial assignment from inventor Mohammed N. Islam to Omni Medsci Inc. (executed 2024-02-09, recorded 2024-02-12; Reel 062638/0879). While Omni Medsci Inc. does not manufacture products and commercializes patents through partnerships, this specific transaction is an initial assignment to the corporate entity rather than a subsequent transfer from an operating company to a shell.

  2. Known asserter in the chain — Present. Omni Medsci Inc. has been identified by RPX Corporation and Unified Patents as a non-practicing entity (NPE). The company has filed multiple infringement lawsuits against major technology companies like Fossil, OnePlus, Oura Health, and Samsung, and previously against Apple.

  3. Repeat correspondent across the chain — Not present. There is only one recorded assignment for this patent (Reel 062638/0879), and the correspondent is Omni Medsci Inc. itself.

  4. Cascading transfers — Not present. Only one assignment is recorded for this patent (Reel 062638/0879).

  5. Pre-litigation transfer — Unclear. The assignment from the inventor to Omni Medsci Inc. occurred on February 9, 2024, prior to the patent's issuance on January 14, 2025. Litigation against defendants like Fossil, OnePlus, Oura Health, and Samsung regarding related patents by Omni Medsci Inc. was initiated in late 2024 or early 2025 (e.g., case 2:24-cv-01070). While the initial assignment to Omni Medsci Inc. occurred before this patent was asserted, it is an inventor-to-company transfer, which is standard. The company was already engaged in patent assertion activities with other patents at that time.

  6. Bankruptcy fire-sale — Not present.

  7. Privateering — Unclear. Omni Medsci Inc. claims it commercializes its patents through partnerships rather than manufacturing. This business model could involve privateering, but direct evidence of an operating company transferring the patent to Omni Medsci Inc. to assert against competitors is not explicitly stated for this patent.

  8. Defensive aggregator (anti-NPE) — Not present. The patent is actively being asserted in litigation, not held by a defensive aggregator.

Verdict

NPE — high confidence

The verdict is high confidence NPE because Omni Medsci Inc. has been identified as a known asserter by industry trackers like RPX and Unified Patents. Furthermore, the company explicitly states it does not manufacture or sell patented products, instead relying on partnerships and litigation for commercialization. This patent is currently involved in multiple infringement lawsuits, underscoring its role as an assertion vehicle.

For verification, see the USPTO Patent Assignment Search for US12193790: https://assignmentcenter.uspto.gov/

Generated 5/25/2026, 6:49:02 PM